7808 postmenopausal female patients with osteoporosis were randomized to receive 60 mg of denosumab or placebo every six months for 3 years. Over the course of the study, non-vertebral fractures occurred in 303 patients in the denosumab group (386 fractures) and 364 in the placebo group (465 fractures). 79 of the fractures in the denosumab group and 120 fractures in the placebo group were treated with surgery. Delayed healing was seen in 2 denosumab patients and 5 placebo patients. Lastly, a significantly smaller proportion of patients in the denosumab group experienced a complication associated with a fracture or its management.